Xianlu Zhang
Overview
Explore the profile of Xianlu Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
8
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hu J, Miao Q, Ren J, Su H, Zhang X, Bi J, et al.
Cancer Cell Int
. 2025 Feb;
25(1):44.
PMID: 39948672
Background And Aim: Prostate cancer is the most common male malignancy. Current diagnostic methods using single TPSA and PHI lack specificity. Some researches have created nomograms for predicting risk, but...
2.
Chen Y, Zhang X, Bi J, Wang J
Acad Radiol
. 2025 Feb;
PMID: 39915184
Rationale And Objectives: Positron emission tomography/computed tomography (PET/CT) is an important modality for the diagnosis of prostate cancer (PCa), yet the choice of radiotracers has not been clearly defined. This...
3.
Zhang X, Hu J, Zheng H, Ren J, Mu S, Chen Y, et al.
Sci Rep
. 2024 Dec;
14(1):31460.
PMID: 39732963
To evaluate the predictive utility of N6-methyladenosine (m6A)-associated long non-coding RNAs (lncRNAs) for the prognosis and immunotherapy response in papillary renal cell carcinoma (pRCC). Transcriptomic data of pRCC samples were...
4.
Zhang X, Zhang G, Wang J, Bi J
World J Surg Oncol
. 2023 Mar;
21(1):80.
PMID: 36872312
Objective: The purpose of this network meta-analysis was to compare the effectiveness and adverse effects of limited, standard, extended, and super-extended pelvic lymph node dissection (PLND) following radical prostatectomy. Methods:...
5.
Zhang X, Zhang G, Wang J, Bi J
Front Endocrinol (Lausanne)
. 2023 Feb;
14:1131033.
PMID: 36843606
Background: Second-generation androgen receptor inhibitors (ARIs) have been developed and approved for treating castration-resistant prostate cancer (CRPC). There is a lack of direct comparison of the therapeutic effects and adverse...
6.
Zhang X, Zhang G, Wang J, Wang Y
Front Endocrinol (Lausanne)
. 2023 Feb;
14:1131715.
PMID: 36814583
Background: Orchiectomy has been replaced by medication represented by luteinizing hormone-releasing hormone (LHRH) agonist as the first-line therapy for androgen deprivation therapy (ADT). After the wide application of LHRH agonist,...